Long‐term efficacy and safety of mitapivat in non‐transfusion‐dependent α‐ or β‐thalassaemia: An open‐label phase 2 study
Kevin H.M. Kuo(University Health Network), Hanny Al‐Samkari(Harvard University), Jayme L. Dahlin(Brigham and Women's Hospital), Mark Layton(Age UK), Shihao Shen(Tianjin University), Elliott Vichinsky(Unknown), Keely Gilroy(Agios Pharmaceuticals (United States)), Ashutosh Lal(Post Graduate Institute of Medical Education and Research), Gavrielle M. Price(Agios Pharmaceuticals (United States)), Jeremie H. Estepp(St. Jude Children's Research Hospital)
Cited by 4
Related Papers
Sickle cell disease
|Nature Reviews Disease Primers|2018|1.4k
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848
MATS: a Bayesian framework for flexible detection of differential alternative splicing from RNA-Seq data
|Nucleic Acids Research|2012|402
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320